-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $40

Benzinga·12/26/2025 15:02:01
语音播报
Leerink Partners analyst Andrew Berens maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $34 to $40.